163 related articles for article (PubMed ID: 15828852)
21. Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.
Inotsume N; Nishimura M; Fujiyama S; Sagara K; Sato T; Imai Y; Matsui H; Nakano M
Eur J Clin Pharmacol; 1989; 36(5):517-20. PubMed ID: 2568929
[TBL] [Abstract][Full Text] [Related]
22. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease.
Morgan MY; Stambuk D; Cottrell J; Mann SG
Aliment Pharmacol Ther; 1990 Feb; 4(1):83-96. PubMed ID: 2104076
[TBL] [Abstract][Full Text] [Related]
24. Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age.
Cirillo I; Vaccaro N; Castaneda-Ruiz B; Redman R; Cossey V; Bradley JS; Allegaert K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4742-9. PubMed ID: 26014957
[TBL] [Abstract][Full Text] [Related]
25. Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
Furuta K; Adachi K; Komazawa Y; Mihara T; Miki M; Azumi T; Fujisawa T; Katsube T; Kinoshita Y
J Gastroenterol Hepatol; 2006 Oct; 21(10):1581-5. PubMed ID: 16928220
[TBL] [Abstract][Full Text] [Related]
26. Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.
Kim J; Ogai A; Nakatani S; Hashimura K; Kanzaki H; Komamura K; Asakura M; Asanuma H; Kitamura S; Tomoike H; Kitakaze M
J Am Coll Cardiol; 2006 Oct; 48(7):1378-84. PubMed ID: 17010798
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers.
Gao S; Liu GL; Wang SX; Gao XH
Zhongguo Yao Li Xue Bao; 1991 May; 12(3):195-8. PubMed ID: 1781278
[TBL] [Abstract][Full Text] [Related]
28. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of piritramide in newborns, infants and young children in intensive care units.
Müller C; Kremer W; Harlfinger S; Doroshyenko O; Jetter A; Hering F; Hünseler C; Roth B; Theisohn M
Eur J Pediatr; 2006 Apr; 165(4):229-39. PubMed ID: 16496200
[TBL] [Abstract][Full Text] [Related]
30. Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
Adachi K; Komazawa Y; Mihara T; Azumi T; Fujisawa T; Katsube T; Furuta K; Kinoshita Y
J Gastroenterol Hepatol; 2005 Jul; 20(7):1012-5. PubMed ID: 15955208
[TBL] [Abstract][Full Text] [Related]
31. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
Orenstein SR; Gremse DA; Pantaleon CD; Kling DF; Rotenberg KS
Clin Ther; 2005 Apr; 27(4):472-83. PubMed ID: 15922820
[TBL] [Abstract][Full Text] [Related]
32. Saturable urinary excretion kinetics of famotidine in the dog.
Boom SP; Hoet S; Russel FG
J Pharm Pharmacol; 1997 Mar; 49(3):288-92. PubMed ID: 9231347
[TBL] [Abstract][Full Text] [Related]
33. Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery.
Su F; Gastonguay MR; Nicolson SC; DiLiberto M; Ocampo-Pelland A; Zuppa AF
Anesth Analg; 2016 May; 122(5):1556-66. PubMed ID: 26218862
[TBL] [Abstract][Full Text] [Related]
34. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.
Andersson T; Hassall E; Lundborg P; Shepherd R; Radke M; Marcon M; Dalväg A; Martin S; Behrens R; Koletzko S; Becker M; Drouin E; Göthberg G
Am J Gastroenterol; 2000 Nov; 95(11):3101-6. PubMed ID: 11095324
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of famotidine after intravenous administration in liver disease.
Ohnishi K
Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
[TBL] [Abstract][Full Text] [Related]
37. Effect of a new H2-blocker, famotidine, in reflux esophagitis among severely handicapped children.
Miyake S; Yamada M; Iwamoto H; Yamashita S; Sugio Y
Clin Ther; 1987; 9(5):548-58. PubMed ID: 2889529
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
Stangier J; Su CA; Roth W
J Int Med Res; 2000; 28(4):149-67. PubMed ID: 11014323
[TBL] [Abstract][Full Text] [Related]
39. Levofloxacin pharmacokinetics in children.
Chien S; Wells TG; Blumer JL; Kearns GL; Bradley JS; Bocchini JA; Natarajan J; Maldonado S; Noel GJ
J Clin Pharmacol; 2005 Feb; 45(2):153-60. PubMed ID: 15647407
[TBL] [Abstract][Full Text] [Related]
40. The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis.
James LP; Stowe CD; Farrar HC; Menendez AA; Argao EA
J Clin Pharmacol; 1999 Dec; 39(12):1242-7. PubMed ID: 10586389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
